Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Unusually-High Trading Volume – Still a Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares saw unusually-strong trading volume on Thursday . 107,552 shares were traded during trading, a decline of 19% from the previous session’s volume of 132,895 shares.The stock last traded at $9.08 and had previously closed at $9.32.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SGIOY. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Finally, Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The company has a current ratio of 1.14, a quick ratio of 1.46 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $15.56 billion, a price-to-earnings ratio of 9.14, a PEG ratio of 3.24 and a beta of 0.08. The stock’s 50 day moving average price is $8.97 and its two-hundred day moving average price is $9.60.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.18. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. On average, analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.